Initial experience with telemonitoring in left ventricular assist device patients.
Left ventricular assist device (LVAD)
device thrombosis
heart failure
hypovolemia
telemonitoring
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Apr 2019
Apr 2019
Historique:
entrez:
12
6
2019
pubmed:
12
6
2019
medline:
12
6
2019
Statut:
ppublish
Résumé
Left ventricular assist devices (LVAD) are increasingly used in patients with end stage heart failure. The HeartAssist 5 and aVAD LVADs offer telemetric monitoring capabilities. Here we report our initial single centre experience with the largest telemonitoring cohort of LVAD patients. Eleven patients (9 males) received a telemonitoring-capable LVAD and were included in our telemonitoring cohort. Waveforms and alarm data were obtained from the telemonitoring system and hospital records were reviewed for clinical data. Mean age at LVAD implantation was 59±5.1 years (mean ± standard deviation). Seven patients had non-ischemic cardiomyopathy and 4 patients had ischemic cardiomyopathy. Median LVEF at implant was 16% (IQR, 15-20%). The total follow-up time was 2,438 patient-days. A total of 6,216 alarm messages were generated in 11 patients. Most common were low flow alarms due to hypovolemia, followed by low flow alarms because of suspected pump thrombosis. One patient died during follow-up, one received a cardiac transplant and one had the LVAD explanted because of pump thrombosis. Pump thrombosis was suspected in 5 patients with 8 episodes of sudden flow decreases and laboratory signs of haemolysis. Real-time telemonitoring of LVAD pump flow, motor speed and power consumption is a promising tool in the follow-up of LVAD recipients. Trending pump flow over hours or days can assist in the early detection of complications, especially flow reductions due to hypovolemia and LVAD thrombosis. Further studies are warranted to delineate the impact of remote monitoring on patients' prognosis.
Sections du résumé
BACKGROUND
BACKGROUND
Left ventricular assist devices (LVAD) are increasingly used in patients with end stage heart failure. The HeartAssist 5 and aVAD LVADs offer telemetric monitoring capabilities. Here we report our initial single centre experience with the largest telemonitoring cohort of LVAD patients.
METHODS
METHODS
Eleven patients (9 males) received a telemonitoring-capable LVAD and were included in our telemonitoring cohort. Waveforms and alarm data were obtained from the telemonitoring system and hospital records were reviewed for clinical data.
RESULTS
RESULTS
Mean age at LVAD implantation was 59±5.1 years (mean ± standard deviation). Seven patients had non-ischemic cardiomyopathy and 4 patients had ischemic cardiomyopathy. Median LVEF at implant was 16% (IQR, 15-20%). The total follow-up time was 2,438 patient-days. A total of 6,216 alarm messages were generated in 11 patients. Most common were low flow alarms due to hypovolemia, followed by low flow alarms because of suspected pump thrombosis. One patient died during follow-up, one received a cardiac transplant and one had the LVAD explanted because of pump thrombosis. Pump thrombosis was suspected in 5 patients with 8 episodes of sudden flow decreases and laboratory signs of haemolysis.
CONCLUSIONS
CONCLUSIONS
Real-time telemonitoring of LVAD pump flow, motor speed and power consumption is a promising tool in the follow-up of LVAD recipients. Trending pump flow over hours or days can assist in the early detection of complications, especially flow reductions due to hypovolemia and LVAD thrombosis. Further studies are warranted to delineate the impact of remote monitoring on patients' prognosis.
Identifiants
pubmed: 31183165
doi: 10.21037/jtd.2018.10.37
pii: jtd-11-S6-S853
pmc: PMC6535490
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S853-S863Déclaration de conflit d'intérêts
Conflicts of Interest: B Lynch is an employee of Reliant Heart Inc., Houston, Texas. The other authors have no conflicts of interest to declare.
Références
ASAIO J. 2005 Jul-Aug;51(4):321-8
pubmed: 16156293
J Am Coll Cardiol. 2010 Apr 27;55(17):1803-10
pubmed: 20413029
Lancet. 2011 Feb 19;377(9766):658-66
pubmed: 21315441
J Cardiovasc Electrophysiol. 2012 May;23(5):515-20
pubmed: 22081967
Europace. 2013 May;15(5):697-703
pubmed: 23258817
J Heart Lung Transplant. 2013 Jan;32(1):1-11
pubmed: 23260699
J Heart Lung Transplant. 2013 Feb;32(2):157-87
pubmed: 23352391
J Heart Lung Transplant. 2013 Jul;32(7):667-70
pubmed: 23796150
Artif Organs. 2014 Mar;38(3):191-8
pubmed: 23902542
Artif Organs. 2014 Apr;38(4):290-7
pubmed: 24102321
J Cardiovasc Electrophysiol. 2014 Jul;25(7):763-70
pubmed: 24602062
N Engl J Med. 2014 Apr 10;370(15):1463-4
pubmed: 24716695
Lancet. 2014 Aug 16;384(9943):583-590
pubmed: 25131977
J Am Coll Cardiol. 2014 Nov 4;64(18):1883-90
pubmed: 25444141
Heart Rhythm. 2015 Jul;12(7):e69-100
pubmed: 25981148
Curr Cardiol Rev. 2015;11(3):246-51
pubmed: 25981314
J Am Coll Cardiol. 2015 Jun 16;65(23):2542-55
pubmed: 26065994
Artif Organs. 2015 Aug;39(8):681-90
pubmed: 26146861
Artif Organs. 2015 Aug;39(8):704-9
pubmed: 26234450
J Cardiothorac Surg. 2015 Aug 08;10:107
pubmed: 26253585
J Am Coll Cardiol. 2015 Dec 15;66(23):2579-2589
pubmed: 26670056
J Am Coll Cardiol. 2015 Dec 15;66(23):2663-2674
pubmed: 26670067
Eur Heart J. 2016 Nov 01;37(41):3154-3163
pubmed: 26984864
Eur J Cardiothorac Surg. 2016 Nov;50(5):834-838
pubmed: 27412342
J Heart Lung Transplant. 2017 Jan;36(1):42-49
pubmed: 27776988
Circ Arrhythm Electrophysiol. 2016 Nov;9(11):
pubmed: 27793958
J Card Surg. 2017 Feb;32(2):162-165
pubmed: 28088844
Herzschrittmacherther Elektrophysiol. 2017 Sep;28(3):257-259
pubmed: 28500612
Stud Health Technol Inform. 2017;236:267-274
pubmed: 28508806
Herzschrittmacherther Elektrophysiol. 2017 Sep;28(3):268-278
pubmed: 28812129
Ann Thorac Surg. 2017 Oct;104(4):e311-e313
pubmed: 28935323